BioCatalystWatch
VKTXWorkspace / VKTX / OverviewCompany library
Viking Therapeutics, Inc. logo

Viking Therapeutics, Inc.

Viking Therapeutics, Inc. (VKTX)

Website

Price
Market cap
Next catalystSAD study completion expected later in 4Q26VK3019 — Phase 1 SAD study · Study completionCompany source ↗
Cash

Chart & Events

Candle interval

Core Clinical

VK2735

GLP-1 receptor × GIP receptor

PreINDP1P2P3FilingApproved
Upcoming / outlook

VK2735 Subcutaneous

GLP-1 receptor × GIP receptor

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

VK2735 Subcutaneous

GLP-1 receptor × GIP receptor

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

VK3019

Amylin receptor × Calcitonin receptor

PreINDP1P2P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

VK3019

Amylin receptor × Calcitonin receptor

PreINDP1P2P3FilingApproved
Upcoming / outlook

VK2735 Subcutaneous

GLP-1 receptor × GIP receptor

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

VK2735 Subcutaneous

GLP-1 receptor × GIP receptor

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

VK2735

GLP-1 receptor × GIP receptor

PreINDP1P2P3FilingApproved
Upcoming / outlook

Other pipelines

VK2809

Thyroid hormone receptor beta (TRβ)

PreINDP1P2P3FilingApproved
VK2809

Thyroid hormone receptor beta (TRβ)

PreINDP1P2P3FilingApproved
DACRA program

Amylin receptor × Calcitonin receptor

PreINDP1P2P3FilingApproved
VK0612

PreINDP1P2P3FilingApproved

History / paused

Thyroid hormone receptor β

PreINDP1P2P3FilingApproved
VK2735 Subcutaneous

GLP-1 receptor × GIP receptor

PreINDP1P2P3FilingApproved
VK2735 Subcutaneous

GLP-1 receptor × GIP receptor

PreINDP1P2P3FilingApproved

GLP-1 receptor × GIP receptor

PreINDP1P2P3FilingApproved

GLP-1 receptor × GIP receptor

PreINDP1P2P3FilingApproved

Androgen receptor (AR)

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Source and basis

Source and basis

Source and basis

Source and basis

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

VKTX PR & News

PR & News

VKTX SEC archive